Intrinsiqq
Kraig Biocraft Laboratories, Inc. logo

Kraig Biocraft Laboratories, Inc. Financials

KBLB

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 17 available years
Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$0–––––
General & Administrative$2$2$2$1$1$1
Research & Development$0$0$0$0$0$0
Total Operating Expenses$3$3$3$3$2$3
Operating Income-$3-$3-$3-$3-$2-$3
Non-Operating
Net Interest Expense-$0-$1-$1-$0-$0-$0
Other Non-Operating Income (Expense)-$2$0$0$0-$2-$5
EBT (Earnings Before Tax)-$6-$4-$3-$3-$4-$8
Net Income
Net Income-$6-$4-$3-$3-$4-$8
Per Share Data
Revenue Per Share$0.00–––––
EPS (Basic)-$0.00$0.00$0.00$0.00$0.00-$0.01
EPS (Diluted)-$0.01$0.00$0.00$0.00$0.00-$0.01
Weighted Avg Shares (Basic)1.12B1.06B1.04B1.03B974.3M877.6M
Weighted Avg Shares (Diluted)1.12B1.06B1.04B1.03B974.3M877.6M
Shares Outstanding1.12B1.06B1.04B1.03B974.3M877.6M

Kraig Biocraft Laboratories (KBLB) financials: revenue, profit and margins

Kraig Biocraft Laboratories (KBLB) generated about n/a in revenue and -$3 million in net income over the trailing twelve months, growing at roughly 255.1% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Kraig Biocraft Laboratories profitable?+

Kraig Biocraft Laboratories reported about -$3 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Kraig Biocraft Laboratories growing?+

Kraig Biocraft Laboratories's revenue has compounded at roughly 255.1% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside KBLB's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 16 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 17 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) · Pick stocks to compare with KBLB

CompareIntrinsic value
HGYNHong Yuan Holding Group Ltd.
$0.03-8.06%35
CANFCan-Fite BioPharma Ltd.
$1.44-2.04%20
ARMPArmata Pharmaceuticals Inc.
$3.03+1.68%30
MNOVMediciNova Inc.
$1.31+3.15%40
LIPOLipella Pharmaceuticals Inc.
$0.00+0.00%25
RLYBRallybio Corporation
$15.47-0.32%62
ALLRAllarity Therapeutics Inc.
$0.79-8.82%0
SLNSilence Therapeutics plc
$19.81+0.00%10

Spot a number that looks wrong? Check it in KBLB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing KBLB

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.